Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 5/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906185 | 0.93 | CYP11B2 (0.52) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL25275679 | 0.93 | CYP11B2 (0.52) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL4271629 | 0.91 | CYP11B2 (0.51) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL24112531 | 0.91 | CYP11B2 (0.51) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL18390155 | 0.91 | CYP11B2 (0.51) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL25270572 | 0.91 | CYP11B2 (0.48) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL14240265 | 0.89 | HPGD (0.46) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL346995 | 0.89 | USP2 (0.56) | CYP11B2ACACBUSP2SMN1; SMN2HPGD | |
| SCHEMBL484311 | 0.89 | CYP11B2 (0.49) | CYP11B2ACACBSCD5USP2SMN1; SMN2 | |
| SCHEMBL25278407 | 0.89 | CYP11B2 (0.49) | CYP11B2ACACBSCD5USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119110802-A | Heterocyclic derivatives substituted with a middle or macrocyclic benzyl group and related uses | 森特萨制药(英国)有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118666945-A | Metabolic stable anti-drug-resistant main protease inhibitor and application thereof in preparing antiviral drugs | 上海市重大传染病和生物安全研究院 | 2024-09-20 | — | — | CN | disclosed |
| CN-116635028-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116583502-A | Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022224278-A1 | COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF | Jubilant Prodel LLC (US) | 2022-10-27 | — | — | WO | disclosed |
| CN-114249712-A | Pyrimidinyl derivatives, method for the production thereof and use thereof | 广州费米子科技有限责任公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9303012-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928868-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2015-08-20 | — | — | US | disclosed |
| US-9056860-B2 | Synthesis of antiviral compound | GILEAD PHARMASSET LLC (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014086806-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| EP-2275421-A1 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | Rottapharm S.p.A. (IT) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232453-A1 | SYNTHESIS OF ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | CYP11B2 1666/4885ACACB 1861/4885SCD5 3321/4885 |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | CNR2, CNR1, GPR52 | CYP11B2 544/4885ACACB 2269/4885SCD5 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.